Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine

Aoyama,Toru; Miyagi,Yohei; Murakawa,Masaaki; Yamaoku,Koichiro; Atsumi,Yosuke; Shiozawa,Manabu; Ueno,Makoto; Morimoto,Manabu; Oshima,Takashi; Yukawa,Norio; Yoshikawa,Takaki; Rino,Yasushi; Masuda,Munetaka; Morinaga,Soichiro

doi:10.3892/ol.2017.5935

Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine

Authors:
- Toru Aoyama
- Yohei Miyagi
- Masaaki Murakawa
- Koichiro Yamaoku
- Yosuke Atsumi
- Manabu Shiozawa
- Makoto Ueno
- Manabu Morimoto
- Takashi Oshima
- Norio Yukawa
- Takaki Yoshikawa
- Yasushi Rino
- Munetaka Masuda
- Soichiro Morinaga
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa 241‑8515, Japan, Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241‑8515, Japan, Department of Hepatobiliary Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa 241‑8515, Japan, Department of Surgery, Yokohama City University, Yokohama, Kanagawa 236‑0004, Japan
Published online on: March 28, 2017 https://doi.org/10.3892/ol.2017.5935
Pages: 3423-3430
Copyright: © Aoyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To the best of our knowledge, the clinical implications of using ribonucleoside reductase subunit M1 (RRM1) in patients who undergo curative resection and adjuvant chemotherapy have not been established. In the present study, the clinical data from 101 consecutive patients who underwent macroscopically curative resection, and who received adjuvant gemcitabine chemotherapy for pancreatic cancer at the Kanagawa Cancer Centre (Yokohama, Kanagawa, Japan) between April 2005 and December 2014 were retrospectively analyzed. The association between the RRM1 status and survival and clinicopathological features were assessed. Of the 101 patients, 41 patients expressed high levels of RRM1 expression (40.6%). Although a significant difference was observed in lymphatic invasion, there was no difference between the two groups with regard to any other clinicopathological parameters. The median follow‑up period was 67.3 months. There was a significant difference between the recurrence‑free survival (RFS) rates at 5 years after surgery, which were 12.9 and 0% in the high RRM1 and low RRM1 groups, respectively (P=0.042). Furthermore, there was a significant difference in the 5‑year overall survival (OS) rates following surgery, which were 5.1 and 21.5% in the high RRM1 and low RRM1 groups, respectively (P=0.015). The results of the present study indicated that out of the factors assessed, RRM1 was the most important prognostic factor for OS and RFS in patients with pancreatic cancer who underwent curative resection followed by adjuvant chemotherapy with gemcitabine. Adjuvant chemotherapy with gemcitabine alone may be insufficient for the treatment of pancreatic cancer, particularly in patients with relevant risk factors.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Nakao A, Fujii T, Sugimoto H, Kanazumi N, Nomoto S, Kodera Y, Inoue S and Takeda S: Oncological problems in pancreatic cancer surgery. World J Gastroenterol. 12:4466–4472. 2006. View Article : Google Scholar : PubMed/NCBI
3	Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, et al: Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 28:219–230. 2004. View Article : Google Scholar : PubMed/NCBI
4	Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G and Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the finnish cancer registry. Gut. 54:385–387. 2005. View Article : Google Scholar : PubMed/NCBI
5	Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H and Büchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 91:586–594. 2004. View Article : Google Scholar : PubMed/NCBI
6	Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
7	Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI
8	Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC and Chung HC: Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics. 16:429–438. 2006. View Article : Google Scholar : PubMed/NCBI
10	Jordheim LP, Sève P, Trédan O and Dumontet C: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12:693–702. 2011. View Article : Google Scholar : PubMed/NCBI
11	Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, et al: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 120:1355–1363. 2007. View Article : Google Scholar : PubMed/NCBI
12	Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ and Maestre J: Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res. 10:4215s–4219s. 2004. View Article : Google Scholar : PubMed/NCBI
13	Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA and Liu X: Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 117:3126–3134. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N and Sueda T: Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery. 153:565–575. 2013. View Article : Google Scholar : PubMed/NCBI
15	Sobin LH and Wittekind CH: TNM Classification of Malignant Tumors. 6th. John Wiley & Sons; New York, NY: 2002
16	Büchler MW, Friess H, Wagner M, Kulli C, Wagener V and Z'Graggen K: Pancreatic fistula after pancreatic head resection. Br J Surg. 87:883–889. 2000. View Article : Google Scholar : PubMed/NCBI
17	Wagner M, Z'graggen K, Vagianos CE, Redaelli CA, Holzinger F, Sadowski C, Kulli C, Zimmermann H, Baer HU and Büchler MW: Pylorus-preserving total pancreatectomy. Early and late results. Dig Surg. 18:188–195. 2001. View Article : Google Scholar : PubMed/NCBI
18	Andrén-Sandberg A, Wagner M, Tihanyi T, Löfgren P and Friess H: Technical aspects of left-sided pancreatic surgery for cancer. Dig Surg. 16:305–312. 1999. View Article : Google Scholar : PubMed/NCBI
19	Seiler CA, Wagner M, Sadowski C, Kulli C and Büchler MW: Randomized prospective trial of pylorus-preserving vs. Classic duodenopancreatectomy (Whipple procedure): Initial clinical results. J Gastrointest Surg. 4:443–452. 2000. View Article : Google Scholar : PubMed/NCBI
20	Valsecchi ME, Holdbrook T, Leiby BE, Pequignot E, Littman SJ, Yeo CJ, Brody JR and Witkiewicz AK: Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer. 12:1042012. View Article : Google Scholar : PubMed/NCBI
21	Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, et al: Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 143:664–674, e1-e6. 2012. View Article : Google Scholar : PubMed/NCBI
22	Xie H, Jiang W, Jiang J, Wang Y, Kim R and Liu X and Liu X: Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 119:173–181. 2013. View Article : Google Scholar : PubMed/NCBI
23	Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, et al: Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 28:2903–2909. 2009. View Article : Google Scholar : PubMed/NCBI
24	Elledge SJ, Zhou Z and Allen JB: Ribonucleotide reductase: Regulation, regulation, regulation. Trends Biochem Sci. 17:119–123. 1992. View Article : Google Scholar : PubMed/NCBI
25	Reichard P: From RNA to DNA, why so many Ribonucleotide reductases? Science. 260:1773–1777. 1993. View Article : Google Scholar : PubMed/NCBI
26	Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M and Danesi R: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther. 5:1387–1395. 2006. View Article : Google Scholar : PubMed/NCBI
27	Povoski SP, Karpeh MS Jr, Conlon KC, Blumgart LH and Brennan MF: Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg. 230:131–142. 1999. View Article : Google Scholar : PubMed/NCBI
28	Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA and Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 236:355–368. 2002. View Article : Google Scholar : PubMed/NCBI
29	Kawai M, Tani M, Terasawa H, Ina S, Hirono S, Nishioka R, Miyazawa M, Uchiyama K and Yamaue H: Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: Prospective study for 104 consecutive patients. Ann Surg. 244:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
30	Munoz-Bongrand N, Sauvanet A, Denys A, Sibert A, Vilgrain V and Belghiti J: Conservative management of pancreatic fistula after pancreaticoduodenectomy with pancreaticogastrostomy. J Am Coll Surg. 199:198–203. 2004. View Article : Google Scholar : PubMed/NCBI
31	Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC, Greve JW, Terpstra OT, Zijlstra JA, Klinkert P and Jeekel H: Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: A prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg. 240:738–745. 2004. View Article : Google Scholar : PubMed/NCBI